Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | MRD for multiple myeloma: is it ready for prime-time?

Philippe Moreau • 10 Sep 2021
IMW 2021
Multiple Myeloma

Philippe Moreau, MD, Nantes University Hospital, Nantes, France, talks on the use of measurable residual disease (MRD) to drive adaptive therapy in multiple myeloma. Prof. Moreau explains the issues surrounding the use of MRD, such as cost and time consumption. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

More from Philippe Moreau

1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
4:49
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
Philippe Moreau • 15 Feb 2023
3:02
Optimal treatment strategies for multiple myeloma
Philippe Moreau • 10 Sep 2021
1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals